Ablation Therapy Combined with EGFR TKIs in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Table 1

General characteristics of included studies.

	Physical ablation joint targeting				Targeted or joint chemotherapy				Combined with chemotherapy	Outcome indicators
	Examples	Men	Women	Phases III-IV	Examples	Men	Women	Phases III-IV
Guo et al., 2016	55	38	17	55	55	37	18	55	Yes, TP	①②③④⑦
Fu et al., 2018	34	24	10	34	34	23	11	34	Yes, TP	①②③④
Guo et al., 2017	43	31	12	43	43	29	14	43	Yes, TP	①②③④
Yu et al., 2019	55	26	29	55	55	28	27	55	No	①②③⑦
Xu et al., 2011	18	0	18	18	18	0	18	18	No	①②③⑤⑥
Zhang et al., 2015	32	Unknown	Unknown	32	32	Unknown	Unknown	32	TP, AP, or GP	①②③④⑦
U.S., 2017	54	Unknown	Unknown	54	54	Unknown	Unknown	54	TP, AP, or GP	①②③④⑦
Chen et al., 2015	40	21	19	40	40	20	20	40	Yes, TP	1 ②③⑥⑦⑧
Zhang, 2016	45	25	20	45	45	24	21	45	Yes, TP	①②③④

Outcome indicators: (1) full remission rate, (2) partial remission rate, (3) disease control rate, (4) quality of life, (5) 1-year survival rate, (6) no progression survival, (7) adverse reactions, and (8) OS.